Characterization of the Mmalton carrier’s cohort within the EARCO (European Alpha- 1 Antitrypsin Research Collaboration) registry

Severe PI*Mmalton patients exhibit clinical and functional similarities to PI*ZZ individuals, suggesting a comparable disease burden. Moderate PI*Mmalton patients, however, show milder impairment. These findings reinforce the need for genotype-specific management strategies and suggest that PI*Mmalton carriers, particularly those with severe variants, should be considered in future clinical trials.

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2025-04-23
DOI
https://doi.org/10.1186/s12890-025-03651-8
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characterization of the Mmalton carrier’s cohort within the EARCO (European Alpha- 1 Antitrypsin Research Collaboration) registry

Carlota Rodríguez‐García, María Torres‐Durán, Hanan A. Tanash, José Luís López-Campos et al.
BMC Pulmonary Medicine
Protease and Inhibitor Mechanisms
article

Characterization of the Mmalton carrier’s cohort within the EARCO (European Alpha- 1 Antitrypsin Research Collaboration) registry

Carlota Rodríguez‐García, María Torres‐Durán, Hanan A. Tanash, José Luís López-Campos, Kenneth R. Chapman, Angelo Guido Corsico, Beatriz Ferraz, Jens‐Ulrik Stæhr Jensen, José María Hernández Pérez, Margarida Fonseca Cardoso, Beatriz Lara, Alice Margaret Turner, Joana Gomes, Marc Miravitlles, Christian Friedrich Clarenbach, Maria Sucena
article en

Abstract

Severe PI*Mmalton patients exhibit clinical and functional similarities to PI*ZZ individuals, suggesting a comparable disease burden. Moderate PI*Mmalton patients, however, show milder impairment. These findings reinforce the need for genotype-specific management strategies and suggest that PI*Mmalton carriers, particularly those with severe variants, should be considered in future clinical trials.

BMC Pulmonary MedicineVol. 25(1)
University of Copenhagen (DK), University Hospitals Birmingham NHS Foundation Trust (GB), University Health Network (CA), Universidade do Porto (PT), University of Toronto (CA), Lund University (SE), University of Pavia (IT), Instituto de Salud Carlos III (ES), University Hospital Complex Of Vigo (ES), Gentofte Hospital (DK), University Hospitals Coventry and Warwickshire NHS Trust (GB), Hospital Universitario Nuestra Señora de Candelaria (ES), Complejo Hospitalario Universitario de Santiago (ES), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), University Hospital of Zurich (CH), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), Hospital de Santo António (PT), Instituto de Biomedicina de Sevilla (ES), Skåne University Hospital (SE), Instituto de Investigación Sanitaria de Santiago (ES), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Hospital Universitario Virgen del Rocío (ES), University of Birmingham (GB)
Sanofi, CSL Behring, European Respiratory Society, Grifols
Partnerships for the goals
Openalex Percentile: Top 89%
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.